Pfizer To Integrate Chai Discovery’s AI Platform To Advance And Scale Molecular Drug Design
Chai Discovery, an organization growing synthetic intelligence fashions for molecular discovery, has introduced a licensing settlement with pharmaceutical firm Pfizer. The firm focuses on making use of AI to drug discovery with the purpose of lowering reliance on conventional trial-and-error strategies. Its fashions are designed to analyse organic buildings and capabilities, generate new molecular candidates,…
